Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Novartis drugs ‘show additive blood pressure reductions’

Novartis drugs ‘show additive blood pressure reductions’

24th July 2007

Novartis has presented the results of a new clinical study showing that administration with Rasilez (aliskiren) and Diovan (valsartan) together results in additive blood pressure reductions in patients.

The results were published in the Lancet, having previously been presented to the congress of the American College of Cardiology, with the trial involving nearly 1,800 high blood pressure patients.

In the trial, 49.3 per cent of patients taking both Rasilez and Diovan reached the recommended blood pressure target of 140/90 mmHg, which compared to 37.4 per cent for those receiving solely Rasilez and 33.8 per cent for those only taking Diovan.

Rasilez received a positive opinion from the Committee for Medicinal Products for Human Use last month, while it was approved in the US in March 2007 under the Tekturna brand name.

James Shannon, global head of development at Novartis Pharma, said: “We are encouraged by these results, because they demonstrate the value of complementary mechanisms of action when Tekturna and Diovan are used together.”

He added that many patients with high blood pressure require at least two forms of medication to effectively control the condition.

In September 2006, Novartis submitted a marketing authorisation application for Rasilez with the European Medicines Agency which included the results of 44 clinical trial involving over 7,800 patients.

We currently have 7 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.